1. P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL. (5th April 2022) Authors: Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗